gilance regulations are always changing, BioSoteria needed its own authoring tool to update course content without relying on expensive specialized programmers,” said Michelle Flewell. “Lectora allows my development team to integrate all types of flash, illustration, audio, and animation files and to modify the content whenever needed, which ensures eLadder Safety courses are not only engaging but always current and reliable.”
Flewell will be joined at the 2010 Lectora User Conference in Cincinnati, Ohio, by speakers from companies such as Pfizer, Procter & Gamble, Dow Chemical, Transperfect Translations and Northrop Grumman. Her presentation will include a discussion of BioSoteria’s unique LMS requirements for delivering its training courses to external clients through the internet, integrating eCommerce and registration, and allowing prospective corporate purchasers to “test drive” eLadder Safety.
About Trivantis Corporation
Trivantis creates world-class elearning software and services that enable the creation, distribution, and management of elearning content. To learn more about how BioSoteria uses Trivantis products, read the case study at the Trivantis website . Trivantis, Lectora and CourseMill are trademarks of Trivantis Corporation.
About eLadder® Safety
BioSoteria’s eLadder Safety is a first-in-class eLearning curriculum in pharmacovigilance. The media-rich courses form a cohesive drug safety training program, with one course building on the other. Rather than a series of repackaged PowerPoint presentations, eLadder online courses are a multimedia experience, with practical engaging exercises and knowledge checks.
To learn more about eLadder Safety,
Page: 1 2 3 Related biology technology :1
Copyright©2010 Vocus, Inc.
All rights reserved
. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust3
. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award 4
. American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety?5
. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI6
. Drug Safety Firm BioSoteria Announces Exponential Growth in 2009 7
. RFID tags to boost transit worker safety8
. FDA researchers identify new MRI safety risk for patients with pacemakers9
. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced10
. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders11
. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS